Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03352557 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease
A Phase 2 study, sponsored by Biogen.
- Terminated
- Registry status
- Phase 2
- Development phase
- 654
- Enrollment target
NCT03352557 is a Phase 2 study that was terminated before completion, run by Biogen. The registered enrollment target is 654 participants.
The verdict
NCT03352557, a Phase 2 study, was terminated before completion, sponsored by Biogen.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 654 participants
- Enrollment target
Study Summary
The primary objective of the placebo-controlled period is to evaluate the safety and tolerability of BIIB092 in participants with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or with mild AD. The secondary objectives of the placebo-controlled period are to evaluate the efficacy of multiple doses of BIIB092 in slowing cognitive and functional impairment in participants with MCI due to AD or with mild AD, and to evaluate the immunogenicity of BIIB092 after multiple doses in participants with MCI due to AD or with mild AD. The primary objective of the long-term extension period is to evaluate the long-term safety and tolerability of BIIB092 in participants with MCI due to AD or with mild AD.
Interventions
- DRUG Placebo
- DRUG BIIB092
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 654 participants |
| Start Date | 2018-05-03 |
| Est. Completion | 2021-08-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03352557
The ClinicalTrials.gov registry entry for NCT03352557 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 654 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03352557 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03352557 about?
NCT03352557 is a clinical study titled "Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease". The primary objective of the placebo-controlled period is to evaluate the safety and tolerability of BIIB092 in participants with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or with mild AD. The secondary objectives of the placebo-controlled period are to evaluate the efficacy of...
What is the current status of trial NCT03352557?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 654 participants. The study started on 2018-05-03. Estimated completion is 2021-08-30.
What interventions are being tested in trial NCT03352557?
The interventions under investigation include: Placebo (DRUG), BIIB092 (DRUG).
Who is sponsoring clinical trial NCT03352557?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.